In mainland China, trastuzumab deruxtecan was first authorized in February 2023 as a monotherapy for the treatment of patients with HER-2-positive adult breast cancer who were either unresectable or had metastasized after receiving one or more anti-HER-2 treatments. Here, ERBB2 is linked to breast cancer.